Prepared for
Pharma
Hero Finding
A vast majority of patients and caregivers find a permanently implanted CNS delivery device acceptable: severe disease burden makes invasive delivery viable, but acceptance is conditional on disease modification.
Across 124 patients and caregivers, the vast majority rated the implanted CNS delivery concept acceptable for brain medication delivery, and a strong majority would be likely to use it if it could meaningfully slow disease progression or reduce symptoms. Acceptance is not unconditional: a meaningful share expressed acceptance contingent on demonstrated therapeutic benefit, and surgical risk concerns remain high. The data show a population willing to accept brain surgery in exchange for disease-modifying efficacy, not symptomatic relief.
Vast majority
Find a permanently implanted CNS delivery device acceptable
Strong majority
Would use the device if it slows progression or reduces symptoms
Strong majority
Express concerns about surgical risks
Meaningful share
Acceptance is conditional on demonstrated therapeutic benefit
Study Design
N=124 patients and caregivers across multiple severe neurological conditions · AI-moderated mixed-method interviews · 60-minute structured guide.
The sample was designed to span the full neurological severity spectrum represented in the sponsor's clinical development plan: adult-onset progressive neurodegenerative disease and adult-and-pediatric severe genetic neurological disease, with both patient and caregiver perspectives where each is the relevant decision-maker.
Sample segmentation
Genetic neurological condition A · 31
Progressive neurodegenerative A · 30
Progressive neurodegenerative B · 30
Genetic neurological condition B · 25
Progressive neurodegenerative C · 8
Interview guide · core topics
- Disease impact on quality of life, daily activities, treatment needs, and caregiver burden
- Current treatment regimen, perceived effectiveness, and unmet therapeutic need
- First impression and acceptability of a permanently implanted CNS delivery device
- Trade-off between surgical invasiveness and disease-modifying benefit
- Conditional acceptance criteria: efficacy thresholds, safety expectations, replacement burden
- Decision-making dynamics: physician, caregiver, family, and peer influence
- Information needs to support adoption: long-term outcomes, safety data, therapeutic benefit evidence
- Willingness to consider clinical trial participation
Recruit criteria
- Diagnosed with one of the severe neurological conditions in the sponsor's clinical development plan (progressive neurodegenerative or severe genetic neurological)
- Or primary caregiver of a patient with one of those conditions
- Symptom severity rated 4 or higher on a 10-point scale (mild cases excluded)
- Patients aged 21 or older for self-report; pediatric perspectives captured via caregiver interviews
Key Findings
What the research surfaced for product strategy.
Six signals defined the acceptability framework, the conditional-use threshold, and the stakeholder communication priorities for clinical development planning.
Vast majority
Find an implanted CNS delivery device acceptable
Strong majority
Would use it if it slows progression or reduces symptoms
Top driver
Cite enhanced efficacy as the leading appeal
Strong majority
Find caregiver or family input influential to the decision
Strong majority
Find the physician recommendation highly influential
01
Current treatments are widely seen as insufficient across all conditions in the basket.
Across the conditions in scope, top-2-box effectiveness ratings for current therapies remain modest, with the most rapidly progressive neurodegenerative cohorts at the lowest ratings. Severe genetic neurological participants report the highest aggregate disease burden across quality of life, treatment needs, and caregiver burden. The unmet need is broad and the population is primed for disease-modifying intervention.
02
Acceptance is conditional on disease modification, not symptomatic relief.
Patients and caregivers consistently distinguish between symptomatic therapies and treatments that alter disease trajectory. Among participants who articulated explicit acceptance criteria, a meaningful share identified disease-modifying efficacy as the threshold requirement. Verbatim language echoes this: 'It has to prove that it slows progression. It has to.' This conditional acceptance is the core commercial framing: the device clears the bar only when paired with a disease-modifying therapeutic.
03
Direct brain access is the most-cited clinical advantage: enhanced efficacy and reduced side effects lead the appeal.
When asked what they liked about the implanted CNS delivery concept, the vast majority cited enhanced treatment efficacy and a strong majority cited reduced systemic side effects. A meaningful share identified rapid, targeted action as the leading benefit, and a smaller share specifically named direct brain access that overcomes the blood-brain barrier. Caregivers emphasize direct brain access more than patients, suggesting different framing for each audience.
04
Patients and caregivers diverge on risk tolerance: patients are more accepting of invasive approaches than caregivers.
Patient mean acceptance of a brain-implanted device is materially higher than caregiver acceptance. A strong majority of patients are enthusiastic about new alternative treatments, versus roughly half of caregivers. Caregivers, however, place more importance on practical device attributes: an essentially universal share rate 'no replacement needed' as significant, versus a strong majority of patients. The communication strategy needs two registers: trajectory and autonomy for patients, burden reduction and durability for caregivers.
05
Surgical concerns are real but tractable: a strong majority concerned about surgical risks; about half identify procedural invasiveness as the key disadvantage.
A strong majority of participants expressed concerns about surgical risks, procedural challenges, and infection risk. About half identified surgical invasiveness as the top disadvantage of the implanted CNS delivery concept overall. These are not deal-breakers in this population but they are the central topics that long-term outcomes data, safety evidence, and physician-led education will need to address.
06
Decision-making is shared between physicians and caregivers: physician recommendation and caregiver or family input both rate as highly influential.
Physician influence is high (a strong majority find it highly influential) and nearly matched by caregiver and family influence (a strong majority find it influential). Other patients also matter: about half find peer recommendations influential. The information participants want most is long-term outcomes, safety data, and therapeutic benefit evidence — the same three pillars across both physician and patient channels.
“I think having something implanted for long-term use is definitely a game changer. Having something that is long-term without any complications or having to change or adjust anything seems too good to be true. That would be something incredible if possible.”— Caregiver, severe genetic neurological care setting
Crosstab · Patient vs. Caregiver
Patients are more accepting of the implanted device; caregivers place more weight on practical device attributes. The gap is largest on enthusiasm for new treatments and on the importance of no replacement.
Acceptance and importance ratings on key device attributes, by respondent type, indexed within row to peak = 100. The patient-caregiver gap defines the dual-register communication strategy required for adoption.
| Patients (n=35) | Caregivers (n=89) | |
|---|---|---|
| Mean acceptance of brain-implanted device | 100 | 80 |
| Mean willingness to consider invasive procedures | 100 | 88 |
| Enthusiastic about new alternative treatments | 100 | 61 |
| Cite direct brain access as a key advantage | 57 | 100 |
| Cite surgical invasiveness as the key disadvantage | 57 | 100 |
| Rate 'no replacement needed' as significant | 78 | 100 |
N=124 across multiple conditionsIndexed · blinded valuesPatients lead on acceptance; caregivers lead on practical-attribute weight
Voice of Patient and Caregiver
How patients and caregivers describe the trade-off.
Verbatims from AI-moderated interviews across all conditions, selected to represent the range of views on disease burden, conditional acceptance, and the patient-caregiver divergence.
Conditional Acceptance · Disease Modification
“I personally consider this a death sentence. Therefore, the potential benefits are any benefit. Any benefit from a device like this is better than the death sentence that people with this condition already have.”
— Caregiver, progressive neurodegenerative care setting
Bar to Entry · Efficacy Threshold
“It has to prove that it slows progression. It has to. Symptomatic relief is not enough at this point. We have lived with that promise for years and it has not changed the trajectory.”
— Patient, progressive neurodegenerative condition
Direct Brain Access · Clinical Advantage
“I think the key advantage is delivery right to the brain rather than having to wait for it to go through the bloodstream for the medicine to kick in. I like the advantage of it being able to work immediately.”
— Caregiver, severe genetic neurological care setting
Caregiver Burden · Practical Appeal
“This new device would be very helpful in taking the responsibility of administration off the caregiver. My daughter is not able to draw her own oral medications, and so this would give me peace of mind that she's getting the medication she needs without missing any doses.”
— Caregiver, severe genetic neurological care setting
Surgical Concern · Procedural Hesitation
“Just like any other brain surgery, it sounds like it can be a bit terrifying, and the thought of leaving an implant in my child's brain does seem very drastic. We would need a lot more information before we could agree to that.”
— Caregiver, severe genetic neurological care setting
Patient Autonomy · Decision Authority
“He has lost so much autonomy that decision making is one of the few things that he absolutely can do. And he guards that very carefully. I can weigh in, and whatever he wants to do, he's going to do.”
— Caregiver, progressive neurodegenerative care setting
Counter-intuitive
The barrier to adoption is not invasiveness; it is proof of disease modification.
The prevailing assumption in invasive therapy development is that surgical risk and implant burden are the primary acceptability barriers. The data shows otherwise. The vast majority of this population already finds an implanted brain device acceptable in concept. What gates actual willingness-to-use is whether the therapy can demonstrably alter disease trajectory: a strong majority would use it if it slows progression or reduces symptoms, and a meaningful share of those with explicit acceptance criteria cite disease-modifying efficacy as the threshold requirement. For sponsors, this reframes the development priority. Surgical risk reduction and implant durability matter, but they are second-order to clinical evidence of disease modification. The market entry investment is in the trial endpoints that prove trajectory change, not in incremental device refinement.
Strategic Implications
Three product and commercial moves from the research.
What the sponsor team carried into clinical development planning, grounded in the conditional-acceptance framework and the patient-caregiver divergence.
01
Anchor the clinical and commercial narrative on disease-modifying efficacy, not symptomatic improvement.
A meaningful share of participants with explicit criteria cite disease modification as the threshold requirement, and a strong majority will use the device if it slows progression or reduces symptoms. Trial endpoints, regulatory positioning, and patient-facing communication should lead with trajectory change. Symptomatic-improvement framing under-sells to a population that has already lived through symptomatic-only treatments and found them insufficient.
02
Build a dual-register communication strategy: trajectory and autonomy for patients, burden reduction and durability for caregivers.
Patients are more accepting of the device and respond to disease-modifying potential. Caregivers are more risk-sensitive but place greater weight on 'no replacement needed' and on direct-brain access for burden reduction. HCP discussion guides, patient education materials, and caregiver support content should differ by audience, not by indication.
03
Invest in long-term outcomes, safety, and therapeutic benefit evidence as the primary information assets.
Participants want long-term outcomes data, safety data, and therapeutic benefit evidence when deciding on adoption. Both physician and caregiver/family channels ask for the same evidence at materially similar rates. A coordinated evidence-generation plan that serves both channels with shared assets is the highest-leverage commercial investment.
Success criteria · 12 months
- Phase 2 readout demonstrates clinically meaningful slowing of disease progression in at least one lead indication
- Patient and caregiver communication assets segmented by audience, validated against the patient-caregiver divergence framework
- Long-term safety and durability evidence package available before launch across the indication basket
Risk register
| Disease-modification endpoint risk in pivotal trials | HIGH |
| Caregiver risk-sensitivity in pediatric indications | HIGH |
| Surgical infrastructure access in community settings | MED |
| Variation in conditional-acceptance thresholds across indications | MED |